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driven by declined annual family income ($56,139 in 2007 to $52,811 in 2010). This 
increasing trend was observed particularly among diabetic patients with low family 
income (2.3% in 2007 to 5.0% in 2010). In the contrast, the financial burden of medica-
tions was relieved for those aged younger than 18 years old (1.8% in 2007 to 0.3% in 
2010). Patients receiving insulins and thiazolidinediones had higher out-of-pocket 
spending as well as financial burden than those used other medications to treat 
diabetes. ConClusions: Patients’ drug costs were reduced successfully between 
2007 and 2010. However, the financial burden of prescription drugs for diabetes 
increased due to decreased family income. Since the use of prescription drugs is a 
vital part of diabetes management, more efforts should be directed to patients with 
low family income in order to improve affordability of prescription drugs.
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ExcEss hEalth carE ExPEnDiturEs associatED with PrEsEncE of 
thyroiD DisorDErs among inDiviDuals with DiaBEtEs: a cost-
DEcomPosition analysis
Raval A.D., Sambamoorthi U.
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objeCtives: To examine the relative contribution of predisposing, enabling, need, 
and external environment factors to the excess health care expenditures associ-
ated with thyroid disorders among individuals with diabetes, compared to indi-
viduals with diabetes and without thyroid disorders. Methods: Cross-sectional 
study design with data on adults over 20 years of age with diabetes (N = 4,920) from 
two years (2009 and 2011) of the Medical Expenditure Panel Survey (MEPS) were 
used. Ordinary least square regressions on log-transformed total expenditures 
were performed to estimate the excess expenditures associated with thyroid dis-
orders after controlling for predisposing, enabling, external environment, life-style 
and need factors as defined framework of the Anderson Behavior and Healthcare 
Utilization Model. Post-regression Blinder-Oaxaca (BO) decomposition analysis was 
performed to examine the relative contribution of factors in explaining the average 
differences in health care expenditures between the two groups. Results: Among 
individuals with diabetes, those with thyroid disorders had greater annual mean 
expenditure compared to those without thyroid disorders ($ 14,289 vs. $10,636, p < 
0.001). After accounting for the predisposing, enabling, external environment, life-
style and need factors, those with thyroid disorders had 15% greater health care 
expenditures compared to those without thyroid disorders. The BO decomposition 
analysis revealed that predisposing, enabling, external environment, life-style and 
need factors explained 63% of the excess health care expenditures among indi-
viduals with thyroid disorders. The excess health care expenditures between the 
groups was predominantly explained by need-factors (43%). Presence of cardiovas-
cular diseases, depression, arthritis, and cancer explained the excess expenditures 
between the groups among the need-factors. ConClusions: Presence of thyroid 
disorders is associated with greater health care expenditures among individuals 
with diabetes. Co-management of co-occurring conditions may reduce the excess 
health care expenditures among individuals with thyroid disorders and diabetes.
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DisaBility aDjustED lifE yEars lost DuE to DiaBEtEs in francE, italy, 
gErmany, sPain anD thE unitED KingDom: a BurDEn of illnEss stuDy
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objeCtives: To compare the burden of disease attributable to diabetes expressed in 
Disability Adjusted Life Years (DALYs) for five European countries in 2010. Methods: 
DALYs lost to diabetes as the sum of years of life lost and years lived with disability 
were estimated by gender and age using country-specific epidemiological data and 
global disability weights. Data from various secondary sources were combined to 
estimate health loss due to diabetes for France, Germany, Italy, Spain and the UK. 
National statistical databases were used and in case necessary, community studies 
were used to derive the prevalence of diabetes by gender and age group which were 
weighted proportionately for a national population burden of disease estimate. All 
identified data were adapted to the Global Burden of Disease methodology (2010) 
to calculate the burden attributable to diabetes. No age weighting and discounting 
was applied. Sensitivity to different sources of variation was examined. Results: 
Germany and Italy lost the largest number of DALYs due to diabetes with 5.9 and 5.8 
per 1,000 inhabitants respectively, followed by Spain (4.4), France (3.7) and the UK 
(2.9). The highest burden was caused by mortality due to diabetes, with the excep-
tion of the UK, for which the burden due to disability of diabetes was higher. This 
may be explained by the way of reporting death in the UK. Mean DALYs lost were 
higher for women in Germany, Italy and Spain and showed to increase with age for 
all countries. Sensitivity analysis in variation in disability weights and uncertainty 
in epidemiological data showed to have effects on DALYs lost. ConClusions: In 
spite of data limitations, the estimates reported here show that DALY loss due to 
diabetes imposes a substantial burden on countries. Cross-national variation in 
disease epidemiology was the largest source of variation in the burden of diabetes 
between countries.
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objeCtives: Alogliptin-pioglitazone (alo-pio) reduces HbA1c levels in treatment-
naïve Type 2 diabetic (T2DM) patients, or those inadequately controlled by mon-
otherapy. Yet, the percentage of patients on alo-pio continuing to meet HbA1c 
thresholds suggested by the National Committee for Quality Assurance (NCQA) 
is unclear but may be important to accountable care organizations (ACOs). This 
analysis examined whether NCQA recognition, aligning with > 40% of patients 
below 7%, > 60% below 8%, and ≤ 15% above 9% HbA1c, is achievable. Methods: 
ied across GLP-1RAs and analyses (ranging from 2.162 [p< 0.001] for exenatide vs. 
exenatide QW among initial adherers, to 0.986 [p= 0.798] for liraglutide 1.8mg vs. 
exenatide QW among initial adherers, to 0.869 [p< 0.001] for liraglutide 1.8mg vs. 
exenatide QW among all patients). ConClusions: Among patients newly initiat-
ing exenatide QW, exenatide, or liraglutide, adherence was consistently highest for 
exenatide QW, while non-persistence varied by analyzed group.
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jaPan
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objeCtives: The personal and economic burden of diabetes is substantial and 
growing in Japan due to its aging population. This study aimed to review the avail-
able literature on the usual treatment of adults with type 2 diabetes (T2DM) in 
Japan. Methods: Systematic search of the scientific literature was performed on 
MEDLINE and EMBASE databases to identify publications about usual care of dia-
betes in Japan written in English or Japanese and published between January 2000 
and May 2013. Included keywords were diabetes mellitus, drug therapy and Japan. 
Randomized clinical trials, comparative or interventional studies were excluded. 
Of 17 publications that met search criteria, 13 pertained to adults with T2DM, of 
which 9 contained original survey data and 4 were literature reviews. Results: 
Almost all of the available data was at least 7 years old. Based on data from 2000 to 
2002, the use of oral anti-diabetic drugs (OAD) alone was the most prevalent treat-
ment option (51.4%), followed by diet alone (25.4%), insulin alone (15.4%), and OAD 
with insulin (7.8%). Although overall, sulfonylureas was the preferred class of OAD 
(61-67%), its use among treatment initiators has dramatically declined from 40% to 
22% following the introduction of dipeptidyl peptidase-4 inhibitors (DPP4) in 2009. 
Since then, the prescription rate of DPP4 increased to nearly 40% due to its perceived 
better safety. ConClusions: Available data on the treatment of diabetes in usual 
care in Japan is rather sparse and not recent. Results indicate that the treatment 
of adults with T2DM in Japan with OAD and insulin is rather similar to that in the 
US and Europe, although the specific OAD in Japan is different. Further research is 
needed on the usual treatment of diabetes in Japan, considering increased longev-
ity, lifestyle changes, ongoing introduction of new medications, changes in disease 
management practices and increased economic concerns.
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objeCtives: Type II Diabetes Mellitus (DM) is exponentially growing in Chile. A 
recent reform aimed at reducing inequities in health care in the country, but the 
gap between social groups continues to grow. We aimed at exploring the exist-
ence of under-diagnosis of type II DM in adult population in Chile. Methods: 
Secondary analysis of cross-sectional Chilean Health Survey 2009-2010 (n= 4767 
adults, weighted sample: 13,347,316). We compared the proportion of adult popula-
tion self-reporting type II DM against the proportion with altered fasting glycae-
mia (value > 126mg/dl, Chi-square test) and then assessed the socio-demographic 
characteristics of those having the condition but ignoring it. For population-rep-
resentative analysis we used Stata 12.0. Results: 48.7% sample were men, mean 
age was 42 years (s.d.:40.8), 56.9% had middle socioeconomic status (SES), followed 
by high and low (18.6%, 24.5%) and 87% lived in urban areas. A 7.8% reported being 
diagnosed with type II DM. There was a significantly higher rate of self-reported 
DM among women than men (5.0% versus 2.8%) and people living in urban versus 
rural settings (6.7% and 1.0%). People with self-reported DM were on average 17 
years older than people without previous diagnosis (mean:57.1). According to lab 
results, 8.4% of the total adult population had type II DM. From this group, over half 
(4.6%) had not been diagnosed with this condition before, representing over 280,000 
people. They are mostly middle-aged men (mean age:46.6) from low and middle SES 
and living in urban areas. ConClusions: We found an under-diagnosis of type II 
DM among middle-aged male adults in Chile. Few recent studies report the urgent 
need to develop community-based strategies to enhance male use of health care, 
particularly to pursue screening consultations even when feeling healthy. This study 
supports such initiative and challenges the complex relationship between gender 
and SES, which could be further explored in Chile.
PDB140
out-of-PocKEt sPEnDing anD financial BurDEn of PrEscriPtion Drugs 
for DiaBEtEs: 2007-2010
Lu K., Yuan J., Wu J.
South Carolina College of Pharmacy – USC Campus, Columbia, SC, USA
objeCtives: To examine the changes in out-of-pocket spending and financial 
burden of prescription drugs for diabetes between 2007 and 2010. Methods: The 
Medical Expenditure Panel Survey for 2007-2010 was analyzed for patients with 
diabetes. Out-of-pocket spending was defined as any self-reported coinsurance and 
deductibles, as well as payments for prescription medications that were not covered 
by insurance. Financial burden for prescription drugs was measured using the pro-
portion of out-of-pocket expenditures divided by total family income in a given year. 
Expenditures for each year were adjusted using Consumer Price Index. Results: 
The out-of-pocket spending for prescription drugs for treating diabetes was dropped 
significantly from $232.5 in 2007 to $197.9 in 2010, while the total expenditure for 
prescription drugs for diabetes increased dramatically from $875.9 to $1026.3 dur-
ing the same period. This declined out-of-pocket spending was observed across 
different age, gender, and racial groups. From 2007 to 2010, the financial burden 
of prescriptions drugs for diabetes increased from 0.8% to 1.1%, which was largely 
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Engel S.S.1
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objeCtives: To assess factors affecting physicians’ decision on why they did not 
initiate dual therapy to untreated Type 2 Diabetes Mellitus (T2DM) patients with 
A1C 7.6–9% per AACE/ACE recommendation. Methods: Primary care physicians 
(PCPs) and specialists in the US were asked to provide medical chart reviews for 4 
patients who were diagnosed with A1C 7.6-9% and initiated with metformin mono-
therapy. Physicians rated 22 reasons on a 5-point Likert scale (1-most irrelevant; 
5-most relevant) on how relevant each reason was for them in treating a specific 
patient. Top 5 reasons ( ≥ 50% of physicians rating the reason as 4 or 5) were identi-
fied. Association of each reason on physician specialty or age was conducted using 
mixed-effect model controlling for physician and patient characteristics. Results: 
1,235 PCPs and 290 specialists participated the study and provided reviews for 5,995 
patients (3,009 young and 2,986 elderly). Four relevant reasons were related to phy-
sicians attitudes and beliefs toward metformin monotherapy and dual therapy: 
R1-“Metformin monotherapy is sufficient to improve glycemic control” (mean[sd]: 
3.66[1.1]); R2 - “Monotherapy is easier to handle than dual therapy” (3.53[1.2]); R3- “I 
believe that monotherapy and changes in lifestyle (e.g. physical activity and dietary 
change) are enough for hyperglycemia control” (3.47[1.1]); and R4- “I recommend 
monotherapy before considering dual therapy” (3.75[1.1]). One relevant reason was 
related to physicians’ perception of patients’ glycemic level: R5 -“Patient has mild 
hyperglycemia” ” (3.27[1.1]). PCPs rated the four reasons more relevant than special-
ists (estimate,[95% CI]) (R1: 0.18,[0.05,0.30]; R2: 0.37,[0.24,0.50]; R3: 0.33,[0.20,0.46]; 
R4: 0.36,[0.23,0.49]. All p< 0.01). Lowering age was also more relevant in the four 
reasons (R1: -0.04,[-0.06,-0.02]; R2: -0.03,[-0.05,-0.02]; R3: -0.02,[-0.03,0.00], R4: -0.06,[-
0.07,-0.04]. All p< 0.02). ConClusions: Guideline non-concordance is related to 
physicians’ attitudes and beliefs toward the therapies and perception of A1C above 
8% as “mild”. The findings have implications for improving T2DM treatment quality.
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longituDinal PattErns of antiDiaBEtEs mEDication PrEscriPtion 
among PrivatEly insurED mEDicarE PatiEnts
Bae J.P, Peng X., Jiang D., Zagar A.
Eli Lilly and Company, Indianapolis, IN, USA
objeCtives: To describe changing diabetes treatment pattern among the elderly 
type 2 diabetes (T2DM) patients during the past 7 years. Methods: A large retro-
spective Medicare patient claims data (MarketScan® Medicare) was longitudinally 
analyzed from 2005 to 2011 to understand T2DM medication use trend. The study 
included 4 major oral antidiabetic medications (i.e., metformin (MET), sulphony-
lurea (SU), thiazolidinediones (TZD), and dipeptidyl peptidase 4 inhibitor (DPP-4)) 
plus injectables (insulin and glucagon-like peptide 1 (GLP-1)) and reported patterns 
of therapy regimens and trends over time. Results: The study identified 453,045 
patients with 1 year enrollment and with T2DM taking one or more antidiabetic 
medications in 2011, compared to 283,484 patients in 2005. The frequently used 
mono therapies in 2011 are MET (22.1%), insulin (12.0%) and SU (10.8%), followed 
by TZD (2.6%), DPP-4 (2.0%), GLP-1 (0.28%). The percentage of patients using MET 
monotherapy increased from 15.0% in 2005 to 22.1% in 2011, while the percentage 
of patients using SU alone decreased from 16.6% in 2005 to 10.8% in 2011. Patients 
taking DPP-4 only increased from 0.03% in 2006 to 2.0% in 2011. Among the combi-
nation therapies in 2011, the most popular one was MET+SU (12.2%), followed by 
MET+DPP-4 (2.9%), MET+SU+DPP-4 (2.8%), MET+TZD (2.8%) and MET+SU+insulin 
(2.3%). The percentage of patients taking any type of insulin rose by 3.4 on from 
24.7% in 2005 to 28.1% in 2011. ConClusions: This study shows changing trends 
in different classes of diabetes medication in this large sample Medicare patients 
over time. Continuing research is needed to monitor anitdiabetic treatment pattern 
change in the future and to understand how these changes are helping to improve 
diabetes care and outcomes.
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mEDication aDhErEncE anD switching ratEs of PatiEnts with 
tEstostEronE rEPlacEmEnt thEraPy (trt) in thE unitED statEs
Puenpatom R.A., Ma L., Camper S.B.
Endo Pharmaceuticals Inc., Malvern, PA, USA
objeCtives: To assess medication adherence and switching rates of testosterone 
replacement therapy (TRT) in the US. Methods: We conducted a retrospective 
claims database study using the MarketScan® Commercial database from January 
2005 through December 2011. The study included men 18-65 years of age who 
had initiated TRT and were diagnosed with hypogonadism or hypogonadotropic 
hypogonadism (ICD-9-CM: 257.3 and 257.4). A minimum of 6 months continuous 
enrollment before and 12 months after the TRT index date was required. Adherence 
was measured by the Mediation Possession Ratio (MPR) and the Proportion of Days 
Covered (PDC), with the adherence rate defined as MPR≥ 0.8. The rate of the first 
switching was summarized by TRT formulation. Results: Of 106,039 patients with 
hypogonadism, the mean MPR and the mean PDC of any TRT during the 360 days 
study period was 0.47 and 0.44, respectively. The overall adherence rate over 12 
months was 21.4% ranging from 28% (pellets), 19.9% (SAIs), 17.7% (gels), 7.8% (buc-
cal), and 6.6% (patch), respectively. Similarly, the average PDCs were significantly 
higher for pellets (0.59) compared to gels (0.43), SAIs (0.39), buccal (0.28), and patch 
(0.27) (P< 0.001). About 13% (n = 13,577) of patients switched from their initial therapy 
to a different TRT formulation. Patients starting with patch were most likely to 
switch to a different formulation (39.3%), followed by patients with SAIs (12.1%), pel-
lets/buccal (12.0%), and gels (10.3%). ConClusions: Our study showed low adher-
ence rates of testosterone replacement therapy among hypogonadism patients. The 
adherence for patients starting on the long-acting testosterone formulation such 
Simulations estimated 1- and 3-year HbA1c progression for 1000 hypothetical 
T2DM patients (average 7 (SE 5.1) years post-diagnosis) to obtain the propor-
tion meeting criteria for < 7%, < 8% and > 9% thresholds by bootstrapping the UK 
Prospective Diabetes Study (UKPDS) 68 equation. UKPDS68 accounts for time, 
HbA1c in the prior year, drug treatment effect, and baseline A1c. Parameter values 
for duration of diabetes, baseline HbA1c, and treatment effect were selected from 
distributions around the mean, and mean values of the latter two were system-
atically varied to approximate different populations and effects. Results: By 1 
year, all NCQA requirements are met when treating patients with alo-pio if aver-
age baseline HbA1c is ≤ 8%. At 3 years, all requirements are met in patients with 
baseline HbA1c ≤ 7.2%, though 8% and 9% threshold requirements are feasible with 
higher baseline HbA1c. Using a more realistic thiazolidinedione durability assump-
tion (annual rosiglitazone HbA1c increase) instead of UKPDS68, all thresholds are 
met at 1 year ≤ 8% baseline HbA1c, and at 3 years with ≤ 7.4% baseline HbA1c. The 
7% and 8% requirements are met with ≤ 8.2% baseline HbA1c at 1 year; at 3 years, 
8% and 9% thresholds can be met with baseline HbA1c ≤ 8-8.2%. ConClusions: 
The simulations show that clinical thresholds can be met at 1 and 3 years, indi-
cating that alo-pio can be considered for treating an appropriate population from 
an ACO perspective.
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objeCtives: Health technology assessment (HTA) agencies and reimbursement 
authorities typically require evidence from randomised controlled trials (RCTs) to 
assess the comparative effectiveness of drugs. For example, for an assessment of 
the GLP-1 receptor agonist exenatide for management of Type 2 diabetes mellitus 
(T2DM), the German Federal Joint Committee (G-BA) pre-specified comparators of 
interest for short- (Byetta®) and long-acting exenatide formulations (Bydureon®) 
in seven indications. The aim of this research was to assess the availability of 
direct or indirect evidence for the benefit of exenatide to support an HTA sub-
mission to the G-BA. Methods: A systematic literature review was conducted 
to identify RCTs comparing exenatide with pharmacological interventions in 
patients with T2DM. Electronic databases (Medline, Embase, Cochrane library: 
accessed October 2013) and clinical trial registries were interrogated. Results: Of 
twenty-nine Byetta® RCTs identified, twenty-seven were inappropriate to provide 
evidence to the G-BA for the following reasons: use of a non-pre-defined compara-
tor (n= 13), background treatment not requested by G-BA (n= 12), or administration 
of a non-licenced Byetta® dose (n= 2). The remaining two studies provided direct 
evidence for two indications. None of the eight Bydureon® RCTs identified were 
appropriate for direct analysis: use of a non-G-BA-required background treat-
ment (n= 7) or comparator (n= 1). For the five indications where no direct evidence 
was available, a single RCT investigating Bydureon® was identified which could 
potentially be used in an indirect comparison against a G-BA required compara-
tor. ConClusions: Despite identification of over thirty RCTs investigating exena-
tide, most of the available evidence would not be considered appropriate by the 
G-BA to assess the benefit of exenatide despite having formed the basis for regula-
tory approval. Regulatory and HTA agencies, reimbursement authorities, and the 
pharmaceutical industry should be aligned on appropriate RCT design to ensure 
the generation of relevant evidence, although this may be challenging given the 
dynamic diabetes treatment environment.
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imPlications for hEalth outcomEs
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objeCtives: Maintaining glycemic control for patients with type 2 diabetes (T2D) 
is associated with a reduced risk of future complications. Proper patient aware-
ness of HbA1c is important to facilitate adherence and improve outcomes. This 
study profiles how HbA1c awareness has changed over time and the consequences 
of poor awareness. Methods: Data from the 2006-2013 US National Health and 
Wellness Survey (NHWS) were used in the analysis (Ns = 62,834 to 75,000 in each 
year). The NHWS is an annual, patient-reported, cross-sectional survey fielded to 
match the demographic characteristics of the US adult population. Patient aware-
ness of their HbA1c levels (i.e., a reported value vs. a “don’t know” response) was 
examined each year. Differences between those who were aware versus unaware 
were made with respect to health status (using the SF-36v2), work productivity 
loss (using the WPAI-GH), and health care resource in a series of regression models 
controlling for demographics and health characteristics. Results: Awareness of 
HbA1c levels improved from 26.6% (in 2006) to 56.4% (in 2013). In 2013, patients who 
are aware (n= 4658) were more likely to be older (60.5 vs. 57.2 years), non-Hispanic 
white (71.4% vs. 61.1%), treating with oral/insulin/non-insulin injectable (87.8% vs. 
76.1%), and more likely to have had diabetic complications compared with those 
who were unaware (n= 3040; all p< .05). Holding demographics and health history 
constant, lack of awareness was associated with poorer health utilities (0.70 vs. 0.68), 
more overall work impairment (17.9% vs. 20.8%), and more hospitalizations in the 
past six months (0.26 vs. 0.22), among other outcomes (all p< .05). ConClusions: 
Awareness of HbA1c has increased over time, though appears disproportionately 
higher among patients of high socioeconomic status and higher risk (i.e., those with 
complications and using insulin). Awareness was also independently associated 
with poorer health outcomes suggesting improved patient education may have 
significant societal benefits.
